JP2023510896A - 局所脂肪減少用気体発泡型ミセル - Google Patents
局所脂肪減少用気体発泡型ミセル Download PDFInfo
- Publication number
- JP2023510896A JP2023510896A JP2022543134A JP2022543134A JP2023510896A JP 2023510896 A JP2023510896 A JP 2023510896A JP 2022543134 A JP2022543134 A JP 2022543134A JP 2022543134 A JP2022543134 A JP 2022543134A JP 2023510896 A JP2023510896 A JP 2023510896A
- Authority
- JP
- Japan
- Prior art keywords
- chemical formula
- compound represented
- polyethylene glycol
- peptide
- gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000693 micelle Substances 0.000 title claims abstract description 118
- 238000005187 foaming Methods 0.000 title claims abstract description 29
- 230000009467 reduction Effects 0.000 title claims abstract description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 95
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 44
- 229920001223 polyethylene glycol Polymers 0.000 claims description 110
- 239000002202 Polyethylene glycol Substances 0.000 claims description 102
- 150000001875 compounds Chemical class 0.000 claims description 97
- 239000000126 substance Substances 0.000 claims description 78
- 150000002334 glycols Chemical class 0.000 claims description 67
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- -1 alkyl chloroformate Chemical compound 0.000 claims description 27
- 239000007789 gas Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 230000008685 targeting Effects 0.000 claims description 20
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 18
- 239000004475 Arginine Substances 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 11
- 239000012046 mixed solvent Substances 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 17
- 239000003446 ligand Substances 0.000 abstract description 8
- 230000004130 lipolysis Effects 0.000 abstract description 8
- 239000013589 supplement Substances 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 230000037213 diet Effects 0.000 abstract description 7
- 235000005911 diet Nutrition 0.000 abstract description 7
- 239000000047 product Substances 0.000 abstract description 6
- 239000007972 injectable composition Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000002093 peripheral effect Effects 0.000 abstract description 2
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- 210000004003 subcutaneous fat Anatomy 0.000 description 10
- 229920001427 mPEG Polymers 0.000 description 9
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 125000005910 alkyl carbonate group Chemical group 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 238000000935 solvent evaporation Methods 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000022534 cell killing Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- VFXVAXFIFHSGNR-UHFFFAOYSA-N octyl carbonochloridate Chemical compound CCCCCCCCOC(Cl)=O VFXVAXFIFHSGNR-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000037237 body shape Effects 0.000 description 3
- 125000005587 carbonate group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000007443 liposuction Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000070 MTS assay Toxicity 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007824 aliphatic compounds Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000617 arm Anatomy 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000000315 cryotherapy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000000694 mesotherapy Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WWQYTEPUEUNBOM-SANMLTNESA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)ON1C(=O)CCC1=O WWQYTEPUEUNBOM-SANMLTNESA-N 0.000 description 1
- GODZNYBQGNSJJN-UHFFFAOYSA-N 1-aminoethane-1,2-diol Chemical compound NC(O)CO GODZNYBQGNSJJN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (12)
- ミセルは、直径が150~500nmであることを特徴とする、請求項1に記載の脂肪減少用気体発泡型ミセル。
- ポリエチレングリコール(polyethylene glycol)及びアルキルクロロホルメート(alkyl chloroformate)を混合して化学式4で表現される化合物であるポリエチレングリコール誘導体を合成する段階;
前記ポリエチレングリコール誘導体に脂肪細胞標的配列(ATS)ペプチド及びr9(arginine)ペプチドからなるグループから選択された一つ以上のペプチドを結合させてペプチドが結合されたポリエチレングリコール誘導体を合成する段階;及び
前記ポリエチレングリコール誘導体及び前記ペプチドが結合されたポリエチレングリコール誘導体をアセトニトリル、メチレンクロリド、クロロホルム及びメタノールから選択される1種又は2種以上の混合溶媒に溶解させた後に溶媒を蒸発させてミセルを合成する段階;を含む下記化学式1で表現される化合物を含むことを特徴とする、脂肪減少用気体発泡型ミセルの製造方法。
化学式4
R1は、水素、C1~5のアルキル基、アミン基、C1~5のアルキルアミン基、カルボキシル基又はC1~5のアルキルカルボキシル基であり、
pは、12~227の整数であり、
qは、2~14の整数であり、
nは、0~3の整数であり、
Lは、脂肪細胞標的配列(ATS)ペプチド又はR9(arginine)ペプチドである。 - 混合溶媒は、メチレンクロリドとアセトニトリルの混合溶媒であり、混合割合は、3~1:1~3であることを特徴とする、請求項5に記載の気体発泡型ミセルの製造方法。
- ポリエチレングリコールの分子量(Mn)は、550~10000であることを特徴とする、請求項5に記載の気体発泡型ミセルの製造方法。
- 請求項1に記載の脂肪減少用気体発泡型ミセルを含むことを特徴とする、脂肪減少用組成物。
- 脂肪減少用組成物が化学式2で表現される化合物及び化学式4で表現される化合物を含む気体発泡型ミセルを含む場合、化学式2で表現される化合物及び化学式4で表現される化合物のモル比は、99.5:0.5~95.0:5.0であり、
脂肪減少用組成物が化学式3で表現される化合物及び化学式4で表現される化合物を含む気体発泡型ミセルを含む場合、化学式3で表現される化合物及び化学式4で表現される化合物のモル比は、99.5:0.5~95.0:5.0であり、
脂肪減少用組成物が化学式2で表現される化合物、化学式3で表現される化合物及び化学式4で表現される化合物を含む気体発泡型ミセルを含む場合、化学式2で表現される化合物、化学式3で表現される化合物及び化学式4で表現される化合物のモル比は、99:0.5:0.5~90.0:5.0:5.0であることを特徴とする、請求項10に記載の脂肪減少用組成物。 - 局所又は静脈注射用として用いられることを特徴とする、請求項9に記載の脂肪減少用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0005470 | 2020-01-15 | ||
KR20200005470 | 2020-01-15 | ||
PCT/KR2020/019197 WO2021145586A1 (ko) | 2020-01-15 | 2020-12-28 | 국소 지방 감소용 기체 발포형 마이셀 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023510896A true JP2023510896A (ja) | 2023-03-15 |
JP7485405B2 JP7485405B2 (ja) | 2024-05-16 |
Family
ID=76864551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022543134A Active JP7485405B2 (ja) | 2020-01-15 | 2020-12-28 | 局所脂肪減少用気体発泡型ミセル |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230096668A1 (ja) |
EP (1) | EP4091602A4 (ja) |
JP (1) | JP7485405B2 (ja) |
KR (1) | KR20210092131A (ja) |
CN (1) | CN115003285B (ja) |
AU (1) | AU2020422088B2 (ja) |
CA (1) | CA3163942A1 (ja) |
MX (1) | MX2022008595A (ja) |
WO (1) | WO2021145586A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230000973A (ko) * | 2021-06-24 | 2023-01-03 | 한양대학교 산학협력단 | 이산화탄소 발생형 나노소재 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010013836A1 (ja) * | 2008-07-29 | 2010-02-04 | ナノキャリア株式会社 | 薬物内包アクティブターゲット型高分子ミセル、医薬組成物 |
JP2014510758A (ja) * | 2011-03-30 | 2014-05-01 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | ほ乳類において脂肪細胞を標的とするための方法および組成物 |
US20150359751A1 (en) * | 2014-06-13 | 2015-12-17 | Industry-University Cooperation Foundation, Hanyang University | Gas-generating nanoparticle |
US20180280548A1 (en) * | 2017-03-22 | 2018-10-04 | Industry-University Cooperation Foundation Hanyang University | Gas-generating polymer micells and manufacturing method of the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100772961B1 (ko) | 2006-08-07 | 2007-11-02 | (주)엠큐어 | 메조테라피/카복시테라피 시술용 복합기 |
SG172298A1 (en) | 2008-12-22 | 2011-07-28 | Myoscience Inc | Integrated cryosurgical system with refrigerant and electrical power source |
KR101447901B1 (ko) * | 2013-04-16 | 2014-10-16 | 한양대학교 산학협력단 | 지방세포 표적 비바이러스성 유전자 전달체 |
KR101494193B1 (ko) * | 2013-08-23 | 2015-02-23 | (주)대성정밀 | 지방분해 복합 시술장치 |
KR20180107745A (ko) * | 2017-03-22 | 2018-10-02 | 한양대학교 산학협력단 | 기체 발포형 마이셀 및 이의 제조방법 |
KR102112702B1 (ko) * | 2019-12-19 | 2020-05-19 | (주)슈퍼노바 바이오 | 표면 개질된 가스-생성 나노입자를 이용한 지방 분해용 조성물 |
-
2020
- 2020-12-28 US US17/758,877 patent/US20230096668A1/en active Pending
- 2020-12-28 CN CN202080093166.6A patent/CN115003285B/zh active Active
- 2020-12-28 MX MX2022008595A patent/MX2022008595A/es unknown
- 2020-12-28 WO PCT/KR2020/019197 patent/WO2021145586A1/ko unknown
- 2020-12-28 AU AU2020422088A patent/AU2020422088B2/en active Active
- 2020-12-28 EP EP20914157.1A patent/EP4091602A4/en active Pending
- 2020-12-28 KR KR1020200184836A patent/KR20210092131A/ko active Search and Examination
- 2020-12-28 CA CA3163942A patent/CA3163942A1/en active Pending
- 2020-12-28 JP JP2022543134A patent/JP7485405B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010013836A1 (ja) * | 2008-07-29 | 2010-02-04 | ナノキャリア株式会社 | 薬物内包アクティブターゲット型高分子ミセル、医薬組成物 |
JP2014510758A (ja) * | 2011-03-30 | 2014-05-01 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | ほ乳類において脂肪細胞を標的とするための方法および組成物 |
US20150359751A1 (en) * | 2014-06-13 | 2015-12-17 | Industry-University Cooperation Foundation, Hanyang University | Gas-generating nanoparticle |
US20180280548A1 (en) * | 2017-03-22 | 2018-10-04 | Industry-University Cooperation Foundation Hanyang University | Gas-generating polymer micells and manufacturing method of the same |
Also Published As
Publication number | Publication date |
---|---|
KR20210092131A (ko) | 2021-07-23 |
CN115003285A (zh) | 2022-09-02 |
WO2021145586A1 (ko) | 2021-07-22 |
EP4091602A4 (en) | 2024-03-06 |
US20230096668A1 (en) | 2023-03-30 |
CN115003285B (zh) | 2024-05-14 |
MX2022008595A (es) | 2022-08-10 |
EP4091602A1 (en) | 2022-11-23 |
JP7485405B2 (ja) | 2024-05-16 |
CA3163942A1 (en) | 2021-07-22 |
AU2020422088A1 (en) | 2022-07-28 |
AU2020422088B2 (en) | 2024-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Singlet oxygen-responsive micelles for enhanced photodynamic therapy | |
KR101697363B1 (ko) | 소수성 제제를 캡슐화하기 위해 사용되는 혼합 입체화학을 가지는 혼성 블록 공중합체 미셀 | |
KR20140041438A (ko) | 약물의 진피 및 전신 전달을 위한 나노입자 | |
CN103429267A (zh) | 疏水分子诱导的支化聚合物集合体及其用途 | |
TWI572369B (zh) | 酸鹼應答型奈米微粒的製備並應用於製備促進抗癌藥物於腫瘤的傳輸與深層滲透之藥物的用途 | |
US20210030897A1 (en) | Bilirubin derivative-based diagnostic and therapeutic ultrasound contrast agent | |
CN114748639B (zh) | 一种光敏剂-羟烷基淀粉-多肽偶联的两亲性大分子化合物、纳米载药系统及其制备方法 | |
US20100278932A1 (en) | Polymer micelles containing sn-38 for the treatment of cancer | |
CN109054000A (zh) | 一种基于聚水杨酸的纳米载药体系及其制备方法和应用 | |
JP2008260705A (ja) | 注射用組成物 | |
JP2023510896A (ja) | 局所脂肪減少用気体発泡型ミセル | |
CN112999159A (zh) | 一种ha介导的靶向双载药阳离子脂质体涂层及其制备方法 | |
Huang et al. | Black phosphorus assisted polyionic micelles with efficient PTX loading for remotely controlled release and synergistic treatment of drug-resistant tumors | |
Zhao et al. | pH-sensitive DOX-loaded PAA-PF127-PAA micelles combined with cryotherapy for treating walker 256 carcinosarcoma in a rat model | |
CN113603877B (zh) | 一种官能化双嵌段共聚物及其制备方法和用途 | |
KR20180107745A (ko) | 기체 발포형 마이셀 및 이의 제조방법 | |
JP2021532164A (ja) | ウイルス送達用ポリマーナノ粒子組成物及びその製造方法 | |
KR102358116B1 (ko) | 기체 발포형 마이셀 및 이의 제조방법 | |
CN115400223A (zh) | 一种二茂铁和tlr7/8激动剂共连接纳米粒及其制备方法和应用 | |
CN105030730A (zh) | 多重靶向抗肿瘤复合制剂及其制备方法 | |
Hu et al. | Polymeric nano-vesicles via intermolecular action to load and orally deliver insulin with enhanced hypoglycemic effect | |
CN103768037A (zh) | 以双亲性化合物为载体的具有抗肿瘤和降低心脏毒性作用的缓释药物纳米微球及其制备方法 | |
KR20230000973A (ko) | 이산화탄소 발생형 나노소재 | |
Hu et al. | Current advances in sustained-release injectable preparations | |
CN117567762B (zh) | 一种提高壬二酸水溶性和稳定性的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240328 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240424 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7485405 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |